Update on Biologicals for ABPA and Asthma
|
|
|
- Olivia Morgan
- 6 years ago
- Views:
Transcription
1 Update on Biologicals for ABPA and Asthma 5 th Advances Against Aspergillosis Istanbul 27 Jan 2012 Richard B. Moss MD Professor of Pediatrics Stanford University Palo Alto CA USA
2 Disease of chronic airway inflammation Characterized by What is Asthma? Episodic reversible airflow obstruction Airway hyper-responsiveness Episodic/Chronic Symptoms Cookson W. Nature 1999; 402S: B5-11
3 Asthma Phenotypes Wenzel S. Lancet 2006;368:804-13
4 Asthma Phenotype and Endotype Phenotype = Observable characteristics and response to treatment Endotype = Subtype by distinct pathophysiologic mechansim Lotvall J et al JACI 2011;127:355-60
5 Lotvall J et al. JACI 2011;127:355-60
6 Spectrum of Pulmonary Disease Caused by Aspergillus Saprophytic: structurally damaged host (bronchiectasis, cavities, necrotic tissue) Aspergilloma (mcyetoma) Chronic necrotizing aspergillosis Allergic: immunocompetent host Asthma/Severe Asthma with Fungal Sensitization (SAFS) Allergic bronchopulmonary aspergillosis (ABPA) Hypersensitivity pneumonitis (allergic alveolitis) Bronchocentric granulomatosis Eosinophilic pneumonia Invasive: immunosuppressed host Angioinvasive aspergillosis Acute bronchopneumonia Pseudomembranous necrotizing tracheobronchitis Invasive pleural disease
7 Potential Targets for New Asthma Drugs Thomson NC et al. BMC Medicine 2011;9:102
8 Diagnostic Criteria for ABPA Five or more of: Asthma Central bronchiectasis on HRCT Immediate skin test reactivity to A. fumigatus Total serum IgE >1000 ng/ml (~417 U/mL) Elevated IgG and/or IgE antibodies to A. fumigatus Pulmonary infiltrates on CXR Serum precipitins to A. fumigatus Eosinophilia
9 Diagnosis of ABPA modified for CF 1. Acute or subacute clinical deterioration (cough, wheeze, exercise intolerance, exercise induced asthma, change in pulmonary function, increased sputum) not attributable to another etiology. 2. Total serum IgE >500 IU/mL. 3. Immediate skin test reactivity, or in vitro demonstration of IgE antibody, to A. fumigatus. 4. One or both of the following: a. Serum precipitins, or IgG antibody, to A. fumigatus. b. New or recent abnormalities on the chest radiograph (infiltrates, mucus plugging) or chest CT (bronchiectasis) that have not cleared with antibiotics and standard physiotherapy. Stevens et al. Clin Infect Dis 2003;37:S225-64
10 Pathogenesis of ABPA Th 17 Courtesy D Hartl
11 Therapeutic Approaches for ABPA Systemic glucocorticosteroids Toxicity Azoles Validated by DBPC RCTs Frequent toxicities (Vori>Itra). Absorption, metabolism, drug interactions mandate drug level monitoring. Resistance. Inhaled amphotericin B Multiple formulations, doses, delivery systems. Pulse IV methylprednisolone Potential for reduced steroid toxicity. Omalizumab
12 Overview of the Allergic Inflammatory Cascade 8
13 IgE Binds to Mast Cells at the High Affinity Receptor (FcεRI) FcεRI binding site IgE molecule FcεRI receptor IgE molecule bound to mast cell Mast cell
14 IgE-dependent Release of Inflammatory Mediators IgE Allergens FcεRI Immediate Release Granule contents: Histamine, TNF-α, Proteases, Heparin Sneezing Nasal congestion Itchy, runny nose Watery eyes Over Minutes Lipid mediators: Prostaglandins Leukotrienes Wheezing Bronchoconstriction Over Hours Cytokine production: Specifically IL-4, IL-13 Mucus production Eosinophil recruitment
15 Omalizumab Blocks IgE Binding to Mast Cells IgE molecule Omalizumab FcεRI receptor Omalizumab binds to CH3 on IgE at FcεRI interaction site Mast cell
16 Omalizumab Prevents the Triggering of Allergic Inflammation
17 Removal of IgE and Down-Regulation of FcεRI by Omalizumab IgE must be reduced >99% for FcεRI to become unoccupied and down-regulated
18 Doses Are Determined by IgE Level and Body Weight Fixed target range for free-ige suppression requires doses determined by individual s pretreatment IgE High pre-rx IgE Low pre-rx IgE IgE IgE IgE IgE IgE IgE IgE IgE IgE IgE IgE IgE IgE IgE IgE IgE IgE IgE IgE IgE IgE + Omalizumab + Omalizumab IgE IgE IgE IgE Target IgE <10 IU/mL Graphical representation assumes patients of equal body weight.
19 Omalizumab Mechanism in IgE-mediated Asthma Reduces mediator release ε-switch Release of IgE B lymphocyte Allergic mediators Plasma cell Allergic Inflammation: eosinophils and lymphocytes Allergens Exacerbation Binds free IgE, reducing cellbound IgE Reduces high-affinity IgE receptors Reduces exacerbations
20 Omalizumab Reduces Exacerbations in Adults with Severe Allergic Asthma Annual exacerbation rate treatment difference Percent reduction p-value INNOVATE study % ETOPA study % <0.001 SOLAR study % Busse study % <0.001 Solèr study % <0.001 Holgate study % ALTO study % (n=2511 O, 1797 P) Pooled % < Humbert M, et al. Allergy 2005; 2. Ayres JG, et al. Allergy 2004; 3. Vignola AM, et al. Allergy Busse W, et al. J Allergy Clin Immunol 2001; 5. Solèr M, et al. Eur Respir J Holgate ST, et al. Clin Exp Allergy 2004; 7. Bousquet J, et al. Allergy 2005
21 Omalizumab Reduces Health Utilization for Severe Asthma Rate per year Omalizumab Control p-value for rate ratio Percent reduction Total emergency visits < % Hospital admissions % Emergency room visits % Unscheduled doctor visit % Bousquet J et al. Allergy 2005;60:302-8
22 Effect of Omalizumab on Symptoms, Exacerbations, and Dose of Inhaled Steroids in Young Urban Asthmatics Reduction 0.48 days/ 2 weeks P< week DBPC RCT in 419 asthmatics 6-20 years old Reduction of 18.5% P<0.001 Reduction 109 µg/d P<0.001 Busse WW et al. NEJM 2011;364:
23 Omalizumab Reduced Exacerbations in Inadequately Controlled Asthma Patients on Optimal ICS-LABA Therapy n= wks yr P=0.008, RR 25% Hanania N A et al. Ann Intern Med 2011;154:573-82
24 Modifying Omalizumab Dosing for ABPA
25 Omalizumab in ABPA Spanish Series 2 of 18 patients in this series had CF Treatment 16 weeks. Follow-up median 36 wks (IQR 28-42) Dose ~600 mg/week Perez-de-Llano LA et al. Thorax 2011; 66:539-40
26 Omalizumab in ABPA French Series 16 adults, no CF Tillie-Lebond I et al. Allergy 2011;66:1254-6
27 Long-term Response to Omalizumab Omalizumab started Omalizumab Gap FEV Annualized FEV1% change: 2 yr prior to omalizumab 9 5 yr on omalizumab Nov-12 May-12 Nov-11 May-11 Nov-10 May-10 Nov-09 May-09 Nov-08 Jun-08 Dec-07 Jun-07 Dec-06 Jun-06 Dec-05 Jun-05 Dec-04 Jun-04 Dec-03 FEV1 Prednisone Tx 6 per. Mov. Avg. (FEV1)
28 Inflammatory Pathways in Asthma Kraft M. NEJM 2011;365:1141-4
29 Anti-IL5 (Mepolizumab) Effect on Severe Exacerbations in Refractory Eosinophilic Asthma DBPC RCT 29 active 32 placebo Monthly x 1 year RR = % CI = p = 0.02 Haldar P et al. NEJM 2009;360:973-84
30 Anti-IL5 (Mepolizumab) Effect on Severe Exacerbations in Refractory Eosinophilic Asthma DBPC RCT 9 active 11 placebo Monthly x 26 wks Nair P et al. NEJM 2009;360:985-93
31 Effect of Reslizumab (Anti-IL5) on Asthma Control and Lung Function in Poorly Controlled Eosinophilic Asthma DBPC RCT Adults 53 active 53 placebo Monthly x 4 Castro M et al. AJRCCM 2011;184:
32 Effect of Lebrikizumab (Anti-IL13) on Lung Function in Adults with Uncontrolled Asthma * *Periostin: an epithelial IL13- induced matricellular protein, marker of T H 2- high endotype Corren J et al. NEJM 2011;365:
33 Eosinophilic T H 2 Asthma RNA Targets - Using Antisense Oligonucleotides AS-ODN ASA4 AS-ODN 143 Inhaled combo TMP ASM8 reduced sputum eos 50% & early asthmatic response Wegmann M.AJRCMB 2011;45: Gauvreau GM et al. AJRCCM 2008;177:952-8
34 Conclusions Asthma is heterogeneous fungal asthma, SAFS and ABPA are forms of allergic/t H 2 endotypic asthma along a severity spectrum Omalizumab (anti-ige) is an effective biological approach to allergic asthma, including ABPA Other biologicals targeting the T H 2 pathway (IL4/13, IL5, eosinophils, others) show promise for selected severe T H 2 endotype asthma/abpa patients Controlled trials of biologics are needed in fungal asthma, SAFS and ABPA
Biologic Therapy in the Management of Asthma. Nabeel Farooqui, MD
Biologic Therapy in the Management of Asthma Nabeel Farooqui, MD None Disclosures Objectives Define severe asthma phenotypes and endotypes Describe the role of biologics in asthma management Review pivotal
Diagnosis and Management of Fungal Allergy Monday, 9-139
Diagnosis and Management of Fungal Allergy Monday, 9-139 13-2010 Alan P. Knutsen,, MD Director, Pediatric Allergy & Immunology Director, Jeffrey Modell Diagnostic Center for Primary Immunodeficiencies
Disclosures. Learning Objective. Biological therapies. Biologics with action against 11/30/2011. Biologic Asthma Therapies and Individualized Medicine
Biologic Asthma Therapies and Individualized Medicine Mark S. Dykewicz, MD Director, Allergy & Immunology Fellowship Program Director Wake Forest University School of Medicine Winston-Salem, North Carolina
Interesting cases in fungal asthma
Interesting cases in fungal asthma Ritesh Agarwal MD, DM Professor of Pulmonary Medicine Postgraduate Institute of Medical Education and Research Chandigarh, India Fungal asthma Broadly defined as the
Searching for Targets to Control Asthma
Searching for Targets to Control Asthma Timothy Craig Distinguished Educator Professor Medicine and Pediatrics Penn State University Hershey, PA, USA Inflammation and Remodeling in Asthma The most important
Phenotypes of asthma; implications for treatment. Medical Grand Rounds Feb 2018 Jim Martin MD DSc
Phenotypes of asthma; implications for treatment Medical Grand Rounds Feb 2018 Jim Martin MD DSc No conflicts to declare Objectives To understand the varied clinical forms of asthma To understand the pathobiologic
Disease spectrum. IPA Invasive pulmonary aspergillosis
Aspergillus & ABPA Disease spectrum IPA Invasive pulmonary aspergillosis ABPA ABPA pathophysiology conidia of Aspergillus trapped in mucous and narrowed airways of asthmatics/cf germinate to form hyphae
Prof Neil Barnes. Respiratory and General Medicine London Chest Hospital and The Royal London Hospital
Prof Neil Barnes Respiratory and General Medicine London Chest Hospital and The Royal London Hospital ASTHMA: WHEN EVERYTHING FAILS WHAT DO YOU DO? South GP CME 2013, Dunedin Saturday 17 th August 2013
Do We Need Biologics in Pediatric Asthma Management?
Do We Need Biologics in Pediatric Asthma Management? Ting Fan LEUNG, MBChB, MD, FRCPCH, FAAAAI Professor and Chairman Department of Paediatrics The Chinese University of Hong Kong Asthma and Allergy by
10/24/2016. Precision Management of Severe Asthma How, When and Where. The Goals of Today s Presentation
1/24/216 Precision Management of Severe Asthma How, When and Where. Reynold A. Panettieri, Jr., MD Vice Chancellor for Clinical & Translational Science Director, Rutgers Institute for Translational and
Biologics in Asthma: Present and Future
Biologics in Asthma: Present and Future Flavia Hoyte, MD Associate Professor of Medicine Fellowship Training Program Director Division of Allergy and Immunology National Jewish Health and University of
Immunomodulators: Anti-IgE mab. Thomas B. Casale, MD Professor of Medicine Chief, Allergy/Immunology Creighton University Omaha, NE
Immunomodulators: Anti-IgE mab Thomas B. Casale, MD Professor of Medicine Chief, Allergy/Immunology Creighton University Omaha, NE Objectives To explain the rationale behind IgE blockade To discuss which
Biologics in asthma Are we turning the corner? Roland Buhl Pulmonary Department Mainz University Hospital
Biologics in asthma Are we turning the corner? Roland Buhl Pulmonary Department Mainz University Hospital Biologics in asthma - are we turning the corner? Allergic asthma anti - IgE Allergic airway inflammation
SEVERE ASTHMA - EVIDENCE TABLES APPENDIX 1
Section 2: Biomarkers Biomarkers to predict response to biologic therapies and macrolides Summary of randomized controlled trials Cut-offs Cut-off selection Study Design N Drug Predictive ability to identify
Immunology of Asthma. Kenneth J. Goodrum,Ph. Ph.D. Ohio University College of Osteopathic Medicine
Immunology of Asthma Kenneth J. Goodrum,Ph Ph.D. Ohio University College of Osteopathic Medicine Outline! Consensus characteristics! Allergens:role in asthma! Immune/inflammatory basis! Genetic basis!
Severe Asthma & Exacerbations: Dawn of a New Era?
Severe Asthma & Exacerbations: Dawn of a New Era? Christophe von Garnier Department of Pulmonary Medicine Syndromes, Phenotypes & Endotypes Asthma Syndrome Variable symptoms, expiratory airflow limitation,
Identifying Biologic Targets to Attenuate or Eliminate Asthma Exacerbations
Identifying Biologic Targets to Attenuate or Eliminate Exacerbations exacerbations are a major cause of disease morbidity and costs. For both children and adults, viral respiratory infections are the major
E-1 Role of IgE and IgE receptors in allergic airway inflammation and remodeling
E-1 Role of IgE and IgE receptors in allergic airway inflammation and remodeling Ruby Pawankar, MD, Ph.D. FRCP, FAAAAI Prof. Div of Allergy, Dept of Pediatrics Nippon Medical School Tokyo, Japan pawankar.ruby@gmail.com
Add on therapy in asthma. Local experience in context J Paul Dilworth, Nicola Marks, Lauren Geddes
Add on therapy in asthma Local experience in context J Paul Dilworth, Nicola Marks, Lauren Geddes Programme Omalizumab Evidence and assessment Local Experience Dysfunctional breathing The other effective
Current Asthma Therapy: Little Need to Phenotype. Phenotypes of Severe Asthma. Cellular Phenotypes 12/7/2012
Subbasement Membrane Thickness(µm) 12/7/212 Current Asthma Therapy: Little Need to Phenotype Phenotypes of Severe Asthma Most mild and to some degree moderate asthmatics respond well to currently available
Allergy overview. Mike Levin Division of Asthma and Allergy Department of Paediatrics University of Cape Town Red Cross Hospital
Allergy overview Mike Levin Division of Asthma and Allergy Department of Paediatrics University of Cape Town Red Cross Hospital Adaptive Immune Responses Adaptive immune responses allow responses against
Recent advances in diagnosis and management of ABPA. Arindam SR(Pulmonary Medicine)
Recent advances in diagnosis and management of ABPA Arindam SR(Pulmonary Medicine) Conventional diagnostic criteria for ABPA Primary Episodic bronchial obstruction (asthma) Peripheral blood eosinophilia
The role of fungi in respiratory allergies. David W. Denning University Hospital of South Manchester The University of Manchester
The role of fungi in respiratory allergies David W. Denning University Hospital of South Manchester The University of Manchester Allergic Aspergillus sinusitis Clinical features = nasal obstruction, recurrent
Xolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit)
Line of Business: All Lines of Business Effective Date: August 16, 2017 Xolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit) This policy has been developed through review
Asthma and Its Many Unmet Needs: Directions for Novel Therapeutic Approaches
Asthma and Its Many Unmet Needs: Directions for Novel Therapeutic Approaches William W. Busse,, M.D. University of Wisconsin School of Medicine and Public Health Madison, WI, USA Disclosure Slide Employment
LINEE GUIDA DELL ASMA: UP TO DATE
LINEE GUIDA DELL ASMA: UP TO DATE Azienda Ospedaliera Pisana Università degli Studi di Pisa Pierluigi Paggiaro GINA International Executive Committee, Chairman GINA ITaly Cardio-Thoracic and Vascular Department,
Clinical Implications of Asthma Phenotypes. Michael Schatz, MD, MS Department of Allergy
Clinical Implications of Asthma Phenotypes Michael Schatz, MD, MS Department of Allergy Definition of Phenotype The observable properties of an organism that are produced by the interaction of the genotype
Asthma Hetereogeneity, Phenotypes and Endotypes Choosing the Right Biologic for your Patient
Asthma Hetereogeneity, Phenotypes and Endotypes Choosing the Right Biologic for your Patient Mario Castro MD, MPH Asthma & Airway Translational Research Unit Washington University School of Medicine St.
Bronchiectasis in Adults - Suspected
Bronchiectasis in Adults - Suspected Clinical symptoms which may indicate bronchiectasis for patients Take full respiratory history including presenting symptoms, past medical & family history Factors
Cigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Interleukin (IL)-5 Antagonists: Mepolizumab and Reslizumab Table of Contents Coverage Policy... 1 General Background... 3 Coding/Billing Information... 5
Antifungal treatment of severe asthma
Antifungal treatment of severe asthma David W. Denning University Hospital of South Manchester [Wythenshawe Hospital] The University of Manchester Severe asthma Bel EH, Severe asthma. Breath magazine Dec
Steps to better understand severe asthma in adults
PRESCRIBING IN PRACTICE n Steps to better understand severe asthma in adults Alexandra M Nanzer MRCP and Andrew Menzies-Gow PhD, MB BS Primary care plays an essential role in identifying and supporting
THE PROMISE OF NEW AND NOVEL DRUGS. Pyng Lee Respiratory & Critical Care Medicine National University Hospital
THE PROMISE OF NEW AND NOVEL DRUGS Pyng Lee Respiratory & Critical Care Medicine National University Hospital Pyng_lee@nuhs.edu.sg Asthma Prevalence, Morbidity, Mortality 235 million suffer from asthma
Severe Asthma(s): Can THEY be prevented or reversed?
Severe Asthma(s): Can THEY be prevented or reversed? Sally Wenzel, MD Professor of Medicine UPMC Chair in Translational Airway Biology Disclosures Sally Wenzel, M.D. Grant/Research Support: Boehringer-Ingelheim,
Anti-IgE Treatment In Severe Asthma. Thomas B. Casale, MD Professor of Medicine Chief, Allergy/Immunology Creighton University Omaha, NE
Anti-IgE Treatment In Severe Asthma Thomas B. Casale, MD Professor of Medicine Chief, Allergy/Immunology Creighton University Omaha, NE Relevant Disclosures Financial Relationship/Consulting Fees: Value
Dr Conroy Wong. Professor Richard Beasley. Dr Sarah Mooney. Professor Innes Asher
Professor Richard Beasley University of Otago Director Medical Research Institute of New Zealand Wellington Dr Sarah Mooney Physiotherapy Advanced Clinician Counties Manukau Health NZ Respiratory and Sleep
EFFECTIVE ASTHMA MANAGEMENT IN PRIMARY CARE Severity Assessment, Guidelines, and New Therapeutic Options
Educational Objectives EFFECTIVE ASTHMA MANAGEMENT IN PRIMARY CARE Bradley E. Chipps, MD, FAAP, FACAAI, FAAAAI, FCCP President-Elect, American College of Allergy, Asthma & Immunology Medical Director,
Traiter l asthme sévère par le phénotype. Dr. Alain Michils CUB-Hôpital Erasme
Traiter l asthme sévère par le phénotype Dr. Alain Michils CUB-Hôpital Erasme Darwin 25 mars 2017 Step 5 treatment (GINA 2016) STEP 5 STEP 4 PREFERRED CONTROLLER CHOICE STEP 1 STEP 2 Low dose ICS STEP
Precision Asthma Therapy: Picking the Right Biologic for the Right Patient. The Asthma Umbrella. Asthma. Late onset. Early onset.
recision Asthma Therapy: icking the Right Biologic for the Right atient The Asthma Umbrella Asthma arly onset Late onset Symptoms xacerbations FV1 T H 2 inflammation No or less T H 2 inflammation henotype
Personalized medicine in childhood asthma. Dr Mariëlle Pijnenburg, Erasmus MC Sophia, Rotterdam, NL
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS for your personal use only, as submitted by the author.
L eosinofilo come nuovo target terapeutico. Paola Parronchi
L eosinofilo come nuovo target terapeutico Paola Parronchi XXX Congresso SIAAIC Sezione Toscana IX Congresso Sezione SIAAIC Toscana, Emilia Romagna, San Marino Firenze, 10-11 Ottobre 2014 Benign and sinister
ASTHMA. Dr Liz Gamble BRI
ASTHMA Dr Liz Gamble BRI Diagnosis Clinical: wheeze, breathlessness, chest tightness, cough Variable airflow obstruction: peak flow chart, spirometry with reversibility to bronchodilators Airways hyper-responsiveness
Implications on therapy. Prof. of Medicine and Allergy Faculty of Medicine, Cairo University
Implications on therapy Dr. Hisham Tarraf MD,FRCP(Edinb.) Prof. of Medicine and Allergy Faculty of Medicine, Cairo University Need for better understanding Global health problem Impact on quality of life
A case of allergic bronchopulmonary aspergillosis successfully treated with mepolizumab
Terashima et al. BMC Pulmonary Medicine (2018) 18:53 https://doi.org/10.1186/s12890-018-0617-5 CASE REPORT Open Access A case of allergic bronchopulmonary aspergillosis successfully treated with mepolizumab
Using Patient Characteristics to Individualize and Improve Asthma Care
Using Patient Characteristics to Individualize and Improve Asthma Care Leonard B. Bacharier, M.D. Associate Professor of Pediatrics Clinical Director, Division of Allergy, Immunology, & Pulmonary Medicine
Outcome, classification and management of wheezing in preschool children Paul L.P. Brand
Outcome, classification and management of wheezing in preschool children Paul L.P. Brand Princess Amalia Children s Clinic Isala klinieken, Zwolle the Netherlands p.l.p.brand@isala.nl Valle de la Luna,
Robert Kruklitis, MD, PhD Chief, Pulmonary Medicine Lehigh Valley Health Network
Robert Kruklitis, MD, PhD Chief, Pulmonary Medicine Lehigh Valley Health Network Robert.kruklitis@lvh.com Correlation of a Asthma pathophyisology with basic science Asthma (Physiology) Bronchodilators
Different kinds of asthma, different kinds of therapies
Different kinds of asthma, different kinds of therapies Friday 10 th November 2017 XXXIII Congresso Sezione SIAAIC Toscana Professor Neil Barnes Medical Head Global Respiratory Franchise, GSK Brentford,
Lecture Notes. Chapter 3: Asthma
Lecture Notes Chapter 3: Asthma Objectives Define asthma and status asthmaticus List the potential causes of asthma attacks Describe the effect of asthma attacks on lung function List the clinical features
Fungal (Aspergillus and Candida) infections in Cystic fibrosis
Fungal (Aspergillus and Candida) infections in Cystic fibrosis Malena Cohen-Cymberknoh, MD CF Center Hadassah-Hebrew University Medical Center Jerusalem, Israel Israeli Annual CF Conference, Herzlyia,
Allergy Update. because you depend upon results. Abacus ALS
Allergy Update Abacus ALS ALS ImmunoCAP sigg measurement ImmunoCAP Specific IgG Measures antigen-specific IgG antibodies in human serum and plasma. Part of the natural defence system of the body and develop
Medical Policy An independent licensee of the Blue Cross Blue Shield Association
Xolair (omalizumab) Page 1 of 15 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xolair (omalizumab) Prime Therapeutics will review Prior Authorization requests.
Asma e BPCO: le strategie terapeutiche
Asma e BPCO: le strategie terapeutiche Dott. Marco Contoli ctm@unife.it Sezione di Medicina Interna e Cardio-Respiratoria Dipartimento di Scienze Mediche Università di Ferrara COPD Definition Chronic Obstructive
COPD: From Phenotypes to Endotypes. MeiLan K Han, M.D., M.S. Associate Professor of Medicine University of Michigan, Ann Arbor, MI
COPD: From Phenotypes to Endotypes MeiLan K Han, M.D., M.S. Associate Professor of Medicine University of Michigan, Ann Arbor, MI Presenter Disclosures MeiLan K. Han Consulting Research support Novartis
Lung Disease in Pediatrics: is it all in the Genes?
Lung Disease in Pediatrics: is it all in the Genes? Jay K. Kolls, M.D. Chair, Department of Genetics LSU Health Sciences Center New Orleans, LA Children s s Hospital of Pittsburgh Severe combined immunodeficiency
Original Research Omalizumab Treatment for Severe Atopic Asthma in a Real World Montréal Cohort
Original Research Omalizumab Treatment for Severe Atopic Asthma in a Real World Montréal Cohort David Haile-Meskale 1, Ron Olivenstein, MD 2,3, Toby Mcgovern, PhD 3, Cathy Fugere 3, James G. Martin, MD
Allergen and Environment in Severe Asthma
Allergen and Environment in Severe Asthma Hye-Ryun Kang MD., PhD. Department of Internal Medicine, Seoul National University Hospital Role of Allergen in Asthma Pathogenesis Early response of allergen
Total collapse of the lung in aspergillosis
Thorax (1965), 20, 118. Total collapse of the lung in aspergillosis R. H. ELLIS From the Gloucestershire Royal Hospital, Pulmonary aspergillosis can be divided conveniently into two main types, allergic
Jamie Lee Memorial Lecture ( ) Targets and Outcomes: Mepolizumab, Benralizumab, Reslizumab
Jamie Lee Memorial Lecture (1958-2017) Targets and Outcomes: Mepolizumab, Benralizumab, Reslizumab Larry Borish, M.D. Professor of Medicine and Microbiology University of Virginia Conflict of Interest
Asthma Upate 2018: What s New Since the 2007 Asthma Guidelines of NAEPP?
10:50-11:50am Asthma Update 2018: What s New Since the 2007 National Asthma Guidelines? SPEAKER Christopher H. Fanta, MD Disclosures The following relationships exist related to this presentation: Christopher
Distinguishing Type-2 Asthma
UPDATE ON ASTHMA THERAPY: MATCHING PHENOTYPE TO TREATMENT Sally E. Wenzel, MD Professor of Medicine University of Pittsburgh Asthma Institute@UPMC Subsection Chief of Allergy 1234567 891234 567891 2345678
December 7, 2010 Future Use of Biologics in Allergy and Asthma
December 7, 2010 Future Use of Biologics in Allergy and Asthma Lanny J. Rosenwasser, M.D. Dee Lyons/Missouri Endowed Chair in Immunology Research Professor of Pediatrics Allergy-Immunology Division Childrens
Omalizumab (Xolair ) ( Genentech, Inc., Novartis Pharmaceuticals Corp.) September Indication
( Genentech, Inc., Novartis Pharmaceuticals Corp.) September 2003 Indication The FDA recently approved Omalizumab on June 20, 2003 for adults and adolescents (12 years of age and above) with moderate to
Biologic Agents in the treatment of Severe Asthma
Biologic Agents in the treatment of Severe Asthma Daniel L Maxwell, D.O., FACOI, FAASM Clinical Assistant Professor of Medicine Michigan State University College of Osteopathic Medicine College of Human
Medical Policy An independent licensee of the Blue Cross Blue Shield Association
Xolair (omalizumab) Page 1 of 15 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xolair (omalizumab) Prime Therapeutics will review Prior Authorization requests.
Asthma. - A chronic inflammatory disorder which causes recurrent episodes of wheezing, breathlessness, cough and chest tightness.
Obstructive diseases Asthma - A chronic inflammatory disorder which causes recurrent episodes of wheezing, breathlessness, cough and chest tightness. - Characterized by Intermittent and reversible (the
Disclosures. Update on COPD & Asthma. Update on the Management of COPD. No Pharma Disclosures. NHLBI - Asthma Clinical Research Network
Update on COPD & Asthma Michael C. Peters, M.D. MAS Division of Pulmonary & Critical Care Medicine Cardiovascular Research Institute University of California San Francisco UCSF Primary Care Medicine San
HCT Medical Policy. Bronchial Thermoplasty. Policy # HCT113 Current Effective Date: 05/24/2016. Policy Statement. Overview
HCT Medical Policy Bronchial Thermoplasty Policy # HCT113 Current Effective Date: 05/24/2016 Medical Policies are developed by HealthyCT to assist in administering plan benefits and constitute neither
Predicting, Preventing and Managing Asthma Exacerbations. Heather Zar Department of Paediatrics & Child Health University of Cape Town South Africa
Predicting, Preventing and Managing Asthma Exacerbations Heather Zar Department of Paediatrics & Child Health University of Cape Town South Africa Asthma exacerbations Predicting exacerbation recognising
Biologicals in the management of bronchial asthma. Deepa Shrestha
Biologicals in the management of bronchial asthma Deepa Shrestha Overview of the seminar Burden of asthma and need of biologicals Immunology of asthma Possible targeted therapy Available biologicals used
Eosinophilic lung diseases
Eosinophilic lung diseases Chai Gin Tsen Department of Respiratory and Critical Care Medicine Tan Tock Seng Hospital The eyes do not see what the mind does not know Not very common A high index of suspicion
Distinction and Overlap. Allergy Dpt, 2 nd Pediatric Clinic, University of Athens
Asthma Phenotypes: Distinction and Overlap Nikos Papadopoulos Allergy Dpt, 2 nd Pediatric Clinic, University of Athens Asthma as a syndrome From the Iliad to ADAM 33 and back again Bronchoconstriction,
Safety, PK and PD of ARRY-502, a CRTh2 Antagonist, in Healthy Subjects with a History of Seasonal Allergies
Safety, PK and PD of ARRY502, a CRTh2 Antagonist, in Healthy Subjects with a History of Seasonal Allergies L. Burgess*, L. Anderson, C. Nugent, N. Klopfenstein, C. Eberhardt, L. Carter, C. Kass, S. RojasCaro,
Rising Incidence of Asthma
Controlling Severe Asthma through Advanced Diagnosis and Treatment Strategies James F. Donohue, MD Professor of Medicine Division of Pulmonary and Critical Care Medicine University of North Carolina at
Omalizumab Treatment for Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis
624204AOPXXX10.1177/1060028015624204Annals of PharmacotherapyEmiralioğlu et al research-article2015 Research Report (Original research/clinical trials) Omalizumab Treatment for Allergic Bronchopulmonary
General Comments to the Author: Reviewer #1 Well done!!
REVIEWERS COMMENTS General Comments to the Author: Reviewer #1 Well done!! Reviewer #2 The strengths of this guideline on severe asthma are first, that the set-up is modular with questions that are relevant
Asthma. Rachel Miller, MD, FAAAAI Director Allergy and Immunology New York Presbyterian Hospital. Figure 1 Asthma Prevalence,
Asthma Rachel Miller, MD, FAAAAI Director Allergy and Immunology New York Presbyterian Hospital Figure 1 Asthma Prevalence, 1980-2000 * Gap between 1995-1996 and 1997 indicates a break in trend due to
Asthma Management for the Athlete
Asthma Management for the Athlete Khanh Lai, MD Assistant Professor Division of Pediatric Pulmonary and Sleep Medicine University of Utah School of Medicine 2 nd Annual Sports Medicine Symposium: The Pediatric
#1 cause of school absenteeism in children 13 million missed days annually
Asthma Update 2013 Jennifer W. McCallister, MD, FACP, FCCP Associate Professor Pulmonary & Critical Care Medicine The Ohio State University Wexner Medical Center Disclosures None 2 Objectives Review burden
Meeting the Challenges of Asthma
Presenter Disclosure Information 11:05 11:45am Meeting the Challenge of Asthma SPEAKER Christopher Fanta, MD The following relationships exist related to this presentation: Christopher Fanta, MD: No financial
Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research
Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research Concord Hospital Woolcock Institute of Medical Research Joe has asthma What
COPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013
COPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013 None Disclosures Definitions Asthma Asthma is a chronic inflammatory
Somkiat Wongtim Professor of Medicine Division of Respiratory Disease and Critical Care Chulalongkorn University
Somkiat Wongtim Professor of Medicine Division of Respiratory Disease and Critical Care Chulalongkorn University Asthma-related Comorbidities Comorbid conditions of the upper airways Rhinitis and Sinusitis
Treatment Options for Complicated/Severe Asthma. Henry J. Kanarek, MD Kanarek Allergy Asthma Immunology
Treatment Options for Complicated/Severe Asthma Henry J. Kanarek, MD Kanarek Allergy Asthma Immunology www.kallergy.com 913-451-8555 Asthma Epidemiology World Health Organization, Asthma is one of the
Emerging Challenges in Primary Care: The Role of Type 2 Inflammation in Severe Asthma: Integrating Biologic Therapy to Optimize Outcomes
Emerging Challenges in Primary Care: 2018 The Role of Type 2 Inflammation in Severe Asthma: Integrating Biologic Therapy to Optimize Outcomes 1 Faculty Diego J. Maselli, MD FCCP Assistant Professor of
The Acute & Maintenance Treatment of Asthma via Aerosolized Medications
The Acute & Maintenance Treatment of Asthma via Aerosolized Medications Douglas S. Gardenhire, EdD, RRT-NPS, FAARC Associate Professor and Chairman Department of Respiratory Therapy Objectives Define Asthma.
Asthma - Chronic. Presentations of asthma Cough Wheeze Breathlessness Chest tightness
Asthma - Chronic Definition of asthma Chronic inflammatory disease of the airways 3 components: o Reversible and variable airflow obstruction o Airway hyper-responsiveness to stimuli o Inflammation of
Immunology of Asthma. Kenneth J. Goodrum,Ph. Ph.D. Ohio University College of Osteopathic Medicine
Immunology of Asthma Kenneth J. Goodrum,Ph Ph.D. Ohio University College of Osteopathic Medicine Outline Consensus characteristics/incidence data Immune/inflammatory basis Etiology/Genetic basis Hygiene
Is reslizumab effective in improving quality of life and asthma control in adolescent and adult patients with poorly controlled eosinophilic asthma?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2018 Is reslizumab effective in improving
Asthma Therapy 2017 JOSHUA S. JACOBS, M.D.
Asthma Therapy 2017 JOSHUA S. JACOBS, M.D. BACKGROUND-PREVALENCE Asthma is one of the most common chronic diseases worldwide with an estimated 300 million affected individuals Prevalence is increasing
Lethal pulmonary fungal disease think fungus early
Lethal pulmonary fungal disease think fungus early David W. Denning National Aspergillosis Centre University Hospital of South Manchester The University of Manchester Global Action Fund for Fungal Infections
RESPIRATORY BLOCK. Bronchial Asthma. Dr. Maha Arafah Department of Pathology KSU
RESPIRATORY BLOCK Bronchial Asthma Dr. Maha Arafah Department of Pathology KSU marafah@ksu.edu.sa Jan 2018 Objectives Define asthma (BA) Know the two types of asthma 1. Extrinsic or atopic allergic 2.
Learning the Asthma Guidelines by Case Studies
Learning the Asthma Guidelines by Case Studies Timothy Craig, DO Professor of Medicine and Pediatrics Distinguished Educator Penn State University Hershey Medical Center Objectives 1. Learn the Asthma
Eosinophilia Associated Lung Diseases
Eosinophilia Associated Lung Diseases Stephen P. Peters, MD, PhD, FAAAAI, FACP, FCCP, FCPP Thomas H. Davis Chair in Pulmonary Medicine Chief, Section on Pulmonary Critical Care, Allergy & Immunologic Diseases
Symptoms are worse at night and in the morning and includes cough, whz, chest tightness.
Asthma Review ETIOLOGY Airflow limitation is caused by the following: - bronchoconstriction - mucous pluggin - airway inflammation Sudden death - heavy mucous plugging is common - typically occurs between
Cynthia S. Kelly, M.D. Professor of Pediatrics Eastern Virginia Medical School Division Director Allergy Children s Hospital of The King s Daughters
Cynthia S. Kelly, M.D. Professor of Pediatrics Eastern Virginia Medical School Division Director Allergy Children s Hospital of The King s Daughters Disclosures Speakers bureau of Novartis and Genentech
Potent and Selective CRTh2 Antagonists are Efficacious in Models of Asthma, Allergic Rhinitis and Atopic Dermatitis
Potent and Selective CRTh2 Antagonists are Efficacious in Models of Asthma, Allergic Rhinitis and Atopic Dermatitis Laura L. Carter, Yoshi Shiraishi, Yooseob Shin, Laurence Burgess, Christine Eberhardt,
Current Approaches to Asthma & COPD
10/11/18 Current Approaches to Asthma & COPD Lekshmi Santhosh, M.D. Assistant Professor, Pulm/Critical Care & Hosp Med Primary Care Medicine: Principles & Practice 10.11.2018 Revisiting the Dutch Hypothesis:
MAYA RAMAGOPAL M.D. DIVISION OF PULMONOLOGY & CYSTIC FIBROSIS CENTER
MAYA RAMAGOPAL M.D. DIVISION OF PULMONOLOGY & CYSTIC FIBROSIS CENTER 16 year old female with h/o moderate persistent asthma presents to the ED after 6 hours of difficulty breathing, cough, and wheezing